Safety and immunogenicity of cilgavimab-tixagevimab for COVID-19 pre-exposure prophylaxis in immunocompromised patients

Author:

Fernández-Prada María,Pérez-Martín Jaime Jesús,Cienfuegos-González Paula

Publisher

Elsevier BV

Subject

General Medicine

Reference5 articles.

1. Infection profile of immune-modulatory drugs used in autoimmune diseases: analysis of summary of product characteristic data;Dey;RMD Open.,2022

2. Immune response to influenza and pneumococcal vaccines in adults with inflammatory bowel disease: a systematic review and meta-analysis of 1429 patients;Müller;Vaccine.,2022

3. Consejo Interterritorial. Sistema Nacional de Salud. Recomendaciones de utilización de Evusheld para la prevención de COVID-19 [accessed 10 Oct 2022]. Available from: https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/covid19/docs/Recomendaciones_uso_Evusheld.pdf.

4. Tixagevimab and Cilgavimab (Evusheld) boosts antibody levels to SARS-CoV-2 in patients with multiple sclerosis on b-cell depleters;Conte;Mult Scler Relat Disord.,2022

5. Cardiovascular outcomes after tixagevimab and cilgavimab use for pre-exposure prophylaxis against COVID-19: a population-based propensity-matched cohort study;Birabaharan;Clin Infect Dis.,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3